The Struggle to Do No Harm in Clinical Trials
December 20, 2017
(Nature) – Most people who enter a clinical trial for a cancer immunotherapy have advanced disease. They hope that the treatment, which aims to activate their T cells against cancer, will boost their life expectancy from months to years. In rare cases, however, the pendulum swings the other way and the treatment results in a fatal reaction. Deaths in recent trials for three cancer immunotherapy drugs have put participants, researchers and drug companies on edge, largely because the causes of the deaths are not well understood.